Allergic conjunctivitis
Conditions
Interventions
Epinastine hydrochloride ophthalmic solution, apply 1 drop a time, 4 times daily, in the both eyes.
Sponsors
Mihara eye clinic, medical corporation houjinkai
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients aged 6 years or older 2)Patients diagnosed as allergic conjunctivitis in the both eyes. 3)Patients with moderate or severe ocular pruritus and switching medication after treated with olopatadine hydrochloride ophthalmic solution at the time of informed consent, or requiring switching drugs judged by study doctor.
Exclusion criteria
Exclusion criteria: 1) Patients given immunotherapy (hyposensitization therapy, modulated therapy). 2) Patients with ocular pruritus and hyperemia caused by a disease other than allergic conjunctivitis which will influence drug evaluation. 3) Patients with a history of atopic keratoconjunctivitis, spring catarrh, giant papillary conjunctivitis, corneal herpes, recurrent corneal erosion caused by the frequent occurrence of corneal injury or dry eye. 4) Patients with surgical history in the internal eye (including laser therapy) within 90 days prior to initiation of the clinical research. 5) Patients with possibility taking medicines (including anti-allergic agent, immunosuppressive drugs and adrenal cortex steroid except eye drops) which affect the efficacy of study drug. However, the use of ophthalmic solutions of adrenal cortex steroid is admitted as needed if there is no improvement in symptoms. 6) Females who are or may be pregnant, or lactating 7) Patients with a history of hypersensitivity to study drug or test material. 8) Patients with severe complications (such as immediate hospitalized care is required) which are identified inappropriate for safety reason. 9) Patients who have any other reasons that causes the study doctor to deem a subject unsuitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of patients with improved symptoms, Change in scores of subjective symptoms(at visits), Change in scores of objective findings(at visits) | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in scores of subjective symptoms(in patient diary), compliance status, change of value in questionnaire items | — |
Countries
Japan
Contacts
Public ContactKenichi Mihara
Mihara eye clinic, Mihara eye clinic,
Outcome results
None listed